摘要
【目的】探讨沙库巴曲缬沙坦治疗高血压合并慢性心力衰竭患者的临床效果。【方法】选择2019年2月至2023年3月两院收治的98例高血压合并慢性心力衰竭患者,采用随机数字表法将所有患者分为观察组和对照组,每组49例。比较两组患者治疗前后血压,血清N-末端脑钠肽前体(NT-proBNP)、血管紧张素Ⅱ(AngⅡ)水平,心功能指标[左心室收缩末内径(LVESD)、左心室舒张末内径(LVEDD)、左室射血分数(LVEF)]及用药安全性。【结果】观察组总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组收缩压、舒张压均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组血清NT-proBNP、AngⅡ水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组LVESD、LVEDD低于治疗前,LVEF高于治疗前(P<0.05),且观察组LVESD、LVEDD均低于对照组,LVEF高于对照组(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。【结论】沙库巴曲缬沙坦可降低高血压合并慢性心力衰竭患者血清AngⅡ、NT-proBNP水平,降低血压,改善心功能,且安全可靠。
【Objective】To investigate the clinical efficacy of sacubitril valsartan in the treatment of hypertension with chronic heart failure.【Methods】A total of 98 patients with hypertension and chronic heart failure admitted to the two hospitals from February 2019 to March 2023 were selected.The patients were randomly divided into the observation group and the control group using a random number table,with 49 patients in each group.Blood pressure,serum N-terminal pro brain natriuretic peptide(NT-proBNP),angiotensinⅡ(AngⅡ)levels,cardiac function indicators[left ventricular end systolic diameter(LVESD),left ventricular end diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF)],and medication safety were compared between two groups before and after treatment.【Results】The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the systolic and diastolic blood pressure in both groups were lower than those before treatment,and the value of the observation group was lower than that of the control group,with a statistically significant difference(P<0.05).The serum levels of NT-proBNP and AngⅡin both groups were lower than those before treatment,and those in the observation group were lower than those in the control group with statistically significant difference(P<0.05).LVESD and LVEDD after treatment in both groups were lower than those before treatment,while LVEF was higher than that before treatment(P<0.05).After treatment,both LVESD and LVEDD of the observation group were lower than those of the control group,while LVEF was higher than that of the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).【Conclusion】Sacubitril valsartan can reduce the levels of serum AngⅡand NT-proBNP in patients with hypertension and chronic heart failure,lower blood pressure,improve cardiac function.And it is safe and reliable.
作者
万钧
王文远
WAN Jun;WANG Wenyuan(Department of Internal Medicine,Jiahe Central Township Health Center,Taiqian County,Puyang Henan 457600)
出处
《医学临床研究》
2025年第6期1007-1010,共4页
Journal of Clinical Research
关键词
高血压
心力衰竭
慢性病
缬沙坦
治疗结果
Hypertension
Heart Failure
Chronic Disease
Valsartan
Treatment Outcome
